Study results of Nastech PYY nasal spray for appetite control are impressive

Further studies will provide more detail on the promise of this PYY nasal spray for appetite control.

• "Obesity is now the number one health threat facing Americans today.
• "Nastech's investigational PYY Nasal Spray may provide a new treatment option for obesity that would be non-invasive, easy to administer, and potentially provide a therapeutic option for weight loss.
• "The results gathered to date are encouraging, and it will be exciting to follow this investigational product as it advances through clinical development."
• All subjects received placebo for the first 2 days of the study and were then randomly assigned to one of six treatment schedules for the remaining 6 days.
• The primary objectives of the study were to assess the safety, nasal tolerance, and pharmacokinetics of PYY3-36 Nasal Spray as well as its effect on caloric reduction and initial indications of weight change.
• Subjects in the treatment group receiving PYY before each meal had a reduction in 24-hour calorie intake that started immediately following treatment and continued to decrease over the 6 treatment days of the study.
• By the last day of the study, the group receiving PYY before each meal had reduced daily calorie intake by an average of 648 calories.
• The 24-hour caloric reduction over all days of treatment was related to the number of daily PYY administrations, with those receiving one dose experiencing a mean caloric reduction of 77 calories per day, two doses producing a 197 calorie reduction and those receiving PYY three times daily experiencing an average caloric reduction of 490 calories per day.
• In addition, subjects who reduced calorie intake following PYY treatment did not compensate by consuming a greater number of calories at subsequent meals.
• Nastech Pharmaceutical Company Inc. is an emerging pharmaceutical company dedicated to the development and commercialization of innovative drug delivery technologies and products.